Taiwan · Delayed Price · Currency is TWD StemCyte International Company Description
StemCyte International, Ltd., a biotechnology company, develops cord blood–based cell therapies in the United States and Taiwan.
The company engages in the research and development of biotechnology and cell-based new drugs; supply of cellular materials; and operation of cord blood cell banks.
It also offers umbilical cord blood transplantation and storage services; and cell products and services.
In addition, the company provides REGENECYTE, an allogeneic umbilical cord blood cellular biotherapy for the treatment of cancer, hematological disorders, immune-related conditions, and metabolic disorders, as well as for post-covid, acute stroke, and cerebral palsy.
Further, it develops CB201(CB-NK), an API in preclinical development for the treatment of hematological malignancies.
The company was founded in 1997 and is based in Taipei, Taiwan. StemCyte International, Ltd. is a subsidiary of Diamond Biofund Inc.
| Country | Cayman Islands |
| Founded | 1997 |
| Industry | Miscellaneous Health And Allied Services, Not Elsewhere Classified |
| CEO | Tong-Young Lee |
Contact Details
Address: No. 508, Zhongxiao East Road Taipei, 115 Taiwan | |
| Phone | 886 2 2601 3013 |
| Website | stemcytebio.com |
Stock Details
| Ticker Symbol | 4178 |
| Exchange | Taipei Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| SIC Code | 8090 |
Key Executives
| Name | Position |
|---|---|
| Tong-Young Lee | Chief Executive Officer |